Thrombocytopenia, anasarca, fever, reticulin fibrosis, and organomegaly (TAFRO) 
syndrome is a unique clinicopathologic variant of multicentric Castleman's 
disease that has recently been identified in Japan. Previous reports have shown 
that affected patients typically respond to immunosuppressive therapy, such as 
prednisolone and tocilizumab. However, the optimal treatment for refractory 
TAFRO syndrome, which can be fatal, remains unclear. We herein report a case of 
tocilizumab-resistant TAFRO syndrome successfully treated with cyclosporin A, 
indicating that cyclosporine A may be an alternative therapy for refractory 
TAFRO syndrome.